Thorne HealthTech (NASDAQ:THRN) reported Q2 earnings of $0.15 per share, beating the analyst consensus estimate of $0.06 by 150%. This is a 400% increase over losses of $(0.05) per share from the same period last year. The company also reported quarterly sales of $72.72 million, beating the analyst consensus estimate of $68.46 million by 6.22%. This is a 29.69% increase over sales of $56.07 million the same period last year.